Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22019708 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2L3MBTL1MAPTTDP1KDM4E | |
| SCHEMBL24977970 | 0.81 | MAPT (0.31) | SMN1; SMN2L3MBTL1MAPTTDP1 | |
| SCHEMBL24978541 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2L3MBTL1MAPTTDP1KDM4E | |
| SCHEMBL22020516 | 0.78 | MAPT (0.39) | SMN1; SMN2L3MBTL1MAPTTDP1KDM4E | |
| SCHEMBL22010514 | 0.78 | ACHE (0.50) | SMN1; SMN2L3MBTL1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL30162576 | 0.78 | ACHE (0.50) | SMN1; SMN2L3MBTL1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL22019995 | 0.76 | ACHE (0.48) | SMN1; SMN2L3MBTL1MAPTTDP1KDM4E | |
| SCHEMBL24977994 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1MAPTTDP1KDM4E | |
| SCHEMBL22020099 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1MAPTKDM4EUSP2 | |
| SCHEMBL22019782 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1MAPTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | SMN1; SMN2 2608/4885L3MBTL1 4789/4885MAPT 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.